CA2381187C - Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis - Google Patents
Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis Download PDFInfo
- Publication number
- CA2381187C CA2381187C CA002381187A CA2381187A CA2381187C CA 2381187 C CA2381187 C CA 2381187C CA 002381187 A CA002381187 A CA 002381187A CA 2381187 A CA2381187 A CA 2381187A CA 2381187 C CA2381187 C CA 2381187C
- Authority
- CA
- Canada
- Prior art keywords
- carnitine
- pharmaceutically acceptable
- acceptable salt
- dialysis
- dialytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The method for the treatment of chronic uraemic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Description
INTRAVENOUS CARNITINE FOR THE TREATMENT OF CHRONIC URAEMIC
PATIENTS UNDERGOING PERIODICAL DIALYSIS
The present invention relates to an improved therapeutic method for the treatment of chronic uraemic patients undergoing periodical dialysis.
Background of the invention It is known that patients affected by chronic uraemia, undergoing periodic dialysis, frequently develop a clinical picture characterized by marked muscular asthenia and a sensation of torpor, particularly evident immediately following dialysis and which may often last even for several hours, so making difficult, if not impossible, a full resumption of working activity.
The clinical experts recognise this problem as "post-dialytic syndrome".
A method for treating the post-dialytic syndrome is disclosed in US 4,272,549, issued on June 9, 1981.
US 4,272,549 teaches to treat the "post-dialytic syndrome" by compensating the loss of carnitine occurring during dialytic session.
US 4,272,549 claims a method for alleviating asthenia and muscle weakness in a chronic uraemic patient under regular dialysis treatment, which comprises submitting said patient with a polysaline dialytic solution which contains a quantity of carnitine (intended as L-carnitine throughout the present application), or a pharmaceutically acceptable salt thereof, sufficient to render the molar concentration of carnitine in said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment. Preferred embodiments of the invention provides that the concentration of carnitine in the dialytic solution is substantially equimolar to the concentration of carnitine in the patient's plasma, but a certain excess of carnitine is also provided, for example between 50 and 100 mole per liter of solution. An embodiment of the invention provides the administration of from 3 io to 6 grams of carnitine or an equivalent amount of a pharmaceutically acceptable salt thereof. The preferred embodiment of the invention provides the oral administration of carnitine, in particular on days between haemodialysis of from 3 to 6 grams of carnitine per day.
The oral treatment is coupled with a rather complex treatment with carnitine during the dialytic session, which comprises the administration of carnitine by slow infusion.
On the days of haemodialytic session, carnitine may also be administered partly by the oral route and partly by slow infusion. In this case, the overall quantity of carnitine administered shall not exceed approximately 10 g.
"Slow infusion" stands for an infusion in which the solution containing carnitine, or any of its pharmaceutically acceptable salts, is administered at the rate of 20 to 40 drops per minute.
PATIENTS UNDERGOING PERIODICAL DIALYSIS
The present invention relates to an improved therapeutic method for the treatment of chronic uraemic patients undergoing periodical dialysis.
Background of the invention It is known that patients affected by chronic uraemia, undergoing periodic dialysis, frequently develop a clinical picture characterized by marked muscular asthenia and a sensation of torpor, particularly evident immediately following dialysis and which may often last even for several hours, so making difficult, if not impossible, a full resumption of working activity.
The clinical experts recognise this problem as "post-dialytic syndrome".
A method for treating the post-dialytic syndrome is disclosed in US 4,272,549, issued on June 9, 1981.
US 4,272,549 teaches to treat the "post-dialytic syndrome" by compensating the loss of carnitine occurring during dialytic session.
US 4,272,549 claims a method for alleviating asthenia and muscle weakness in a chronic uraemic patient under regular dialysis treatment, which comprises submitting said patient with a polysaline dialytic solution which contains a quantity of carnitine (intended as L-carnitine throughout the present application), or a pharmaceutically acceptable salt thereof, sufficient to render the molar concentration of carnitine in said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment. Preferred embodiments of the invention provides that the concentration of carnitine in the dialytic solution is substantially equimolar to the concentration of carnitine in the patient's plasma, but a certain excess of carnitine is also provided, for example between 50 and 100 mole per liter of solution. An embodiment of the invention provides the administration of from 3 io to 6 grams of carnitine or an equivalent amount of a pharmaceutically acceptable salt thereof. The preferred embodiment of the invention provides the oral administration of carnitine, in particular on days between haemodialysis of from 3 to 6 grams of carnitine per day.
The oral treatment is coupled with a rather complex treatment with carnitine during the dialytic session, which comprises the administration of carnitine by slow infusion.
On the days of haemodialytic session, carnitine may also be administered partly by the oral route and partly by slow infusion. In this case, the overall quantity of carnitine administered shall not exceed approximately 10 g.
"Slow infusion" stands for an infusion in which the solution containing carnitine, or any of its pharmaceutically acceptable salts, is administered at the rate of 20 to 40 drops per minute.
Particularly favourable therapeutic results were achieved by a method in which carnitine is administered by the oral route to the patient under haemodialytic treatment only on those days during which the patient is not submitted to a dialytic session, while during the actual dialytic session, a dialysing liquid containing carnitine is used.
Such preferred therapeutic method for the treatment of chronic uraemic patients undergoing haemodialysis, included more particularly the following steps:
1) on the days between one haemodialytic session and the next, administration by the oral route to these patients of 3 to 6 g per day of carnitine or any of its pharmaceutically acceptable salts;
2) on the days of haemodialytic session, submission of these patients to dialysis using, as dialysing liquid, a solution containing a quantity of carnitine or of any of its pharmaceutically acceptable salts, sufficient to make a molar concentration of carnitine in the said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
By operating in such a manner, it is possible to avoid the loss of plasma carnitine which otherwise takes place during a haemodialytic session; the concentration of plasma carnitine remaining practically unchanged during the dialytic session.
In this manner, it is possible to avoid the tissue carnitine depletion, which is the long-term consequence of repeated losses of carnitine the patienl: undergoes during the successive dialytic sessions he is submitted to over a prolonged period of time.
Although for this purpose it is shown to be sufficient that the solution for the haemodialysis be equimolar in carnitine with respect to the blood of the patient under dialytic treatment, it is preferred to operate with a slightly more concentrated solution.
In practice, the haemodialysis solution contains 50 to 100, preferably 60 - 80 moles/litre of carnitine or of any of its pharmaceutically acceptable salts.
On the days of haemodialytic session, carnitine may also be administered partly by the oral route and partly by slow infusion. In this case, the overall quantity of carnitine administered shall not exceed approximately 10 g.
The therapeutic method disclosed in US 4,272,549 is effective in treating "post-dialysis syndrome", but presents a cumbersome schedule of treatment. This fact makes some problems to occur. The compliance of the patients, whose quality of life is already heavily affected, about the necessity of taking care by themselves of the oral self administration of a prescribed dosage of carnitine between the 2o dialytic sessions. There is also the problem of carnitine bioavailability through the oral route, which is subject to saturation mechanism and to some restrictions as to the absorption sites (Harper at al. Eur. J. Clin. Pharmacol. 1988; 35(5):555-62 and Matsuda Et Al. Biol Pharm. Bull 1998, Jul; 21 (7):752-5).
Also, the oral administration of carnitine to a chronic uraemic patient may give rise to the accumulation of toxic metabolites.
A recent work by Sloan et al. (Am. J. Kidney Dis. 1998, Aug;
32(2):265-72) demonstrated that oral supplementation of carnitine is 5 effective in improving the quality of life of patients in the early stage of treatment, but the perceived effect was not sustained through long term treatment (six months).
Summary of the invention It has now been found in a totally unexpected manner an io improved therapeutic method for the treatment of chronic uraemic patients undergoing periodical dialysis.
The method for the treatment of chronic uraemic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
As dialysis session both haemodialysis and peritoneal dialysis zo are intended.
The method according to the present invention provides the surprising improvement with respect to the method disclosed in US
4,272,549 to eliminate the need of the oral treatment, without affecting the maintenance of the correction of carnitine deficiency obtained by the administration of carnitine through intravenous route.
In one aspect, the invention provides use of from to 20 mg/kg body weight of L-carnitine or a 5 pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the use is repeated twice a week every 44 hours and then after 68 hours, and wherein the use 10 is repeated after 3 to 4 weeks with 5 mg/kg of body weight of L-carnitine as a maintenance dosage.
In a further aspect, the invention provides use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the amount of L-carnitine or a pharmaceutically acceptable salt thereof is effective to restore the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter using a maintenance dosage of L-carnitine or a pharmaceutically acceptable salt thereof in the venous return line sufficient to maintain blood L-carnitine at the pre-dialytic level.
In a still further aspect, the invention provides use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein from 10 to 20 mg/kg of body weight of L-carnitine or a pharmaceutically acceptable salt thereof, calculated as L-6a carnitine, is used to restore the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter using a maintenance dosage of L-carnitine or a pharmaceutically acceptable salt thereof sufficient to maintain blood L-carnitine at the pre-dialytic level.
According to one aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount of 400 to 3000 mg and is for administration after each dialysis session over a three or four week period three times a week at 44 hour intervals followed by a delay of 68 hours before the next week's first session, and when the three or four week period is over, the L-carnitine or the pharmaceutically acceptable salt is for administration in an amount of 200 to 750 mg as a maintenance dosage following each dialysis session.
According to another aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing pericdic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective for restoration of the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective as a maintenance 6b dosage of in the venous return line sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
According to still another aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein from 400 to 3000 mg of the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration after the dialysis session in restoration of blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration as a maintenance dosage in an amount sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
The invention shall be disclosed in detail, with reference to Figures and Examples.
Brief description of the figures Figure 1 illustrates the treatment schedule, where the letters A-F denote the heart effluent sampling times for the measurement of metabolites.
Figure 2 shows the effect of carnitine (A) and carnitine fumarate (B) on creatine phosphate and ATP.
Figure 3 compares lactate (A) with succinate (B) released by the heart, as measured in the effluent.
Figure 4 illustrates the release of malate.
6c Figure 5 illustrates the release of LDH.
Figure 6 illustrates the production of lactate.
Detailed disclosure of the invention The preferred starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session.
Initiation of the therapy may be prompted by through (pre-dialysis) plasma carnitine concentrations that are below normal (40-50 mol/L). Dose adjustments should be guided by through (pre-dialysis) carnitine concentrations, and downward dose adjustments (for example to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.
Carnitine can be administered as inner salt or in any pharmaceutically acceptable salts thereof.
In the above mentioned patents US 4272549 and US 4272549, the invention is given in detailed manner as to put it into practice.
As far as carnitine is concerned, the active ingredient is mentioned as "carnitine or any of its pharmaceutically acceptable salts" (see for instance US 4272549, column 4, line 16), thus clearly teaching to io the skilled person that any of the pharmaceutically acceptable salts will do in the invention therein disclosed.
In the present invention we confirm that for the practice of the improved method for the treatment of chronic uraemic patients undergoing periodical dialysis, any of the pharmaceutically acceptable salts of carnitine will do. But, in a particular embodiment of the invention, the skilled person might have to face a problem with some patients. During the dialytic session, some patients are affected by hypervolemic heart, and this can give a severe outcome as heart failure. Moreover, a number of patients undergoing 2o hemodialysis are affected by diabetes.
In a particular embodiment of the present invention, it has been found that fumarate of L-carnitine exerts a surprising beneficial effect on heart. Moreover, due to its physiologic role, fumarate may have beneficial effects in diabetic patients.
WO 01/52836 PCT/ITOl/00012 Accordingly, a particular embodiment of the present invention relates to the method above disclosed, wherein fumarate is the pharmaceutically acceptable salt of L-carnitine.
Suitable formulations of carnitine, or a pharmaceutically acceptable salt thereof, are in the form of injectable compositions, for example comprising an equivalent amount of carnitine of 200 mg per 1 mL. A 2.5 or a 5 mL single dose ampoule may be convenient.
When a pharmaceutically acceptable salt of L-carnitine is used, such as fumarate, the amount of active ingredient shall be calculated as to to give an equivalent amount of L-carnitine as above specified.
Description of the preferred embodiment Patients showing a pre-dialysis carnitine level equal or lower than 40-50 M were treated with the method according to the present invention with a 10-20 mg/kg dose of carnitine at the end of the 4-hours dialytic session. According to a standard dialytic schedule, the treatment was repeated twice a week every 44 hours, then after 68 hours. This treatment was continued for 3-4 weeks, monitoring pre-dialytic levels of carnitine. As a further embodiment of the present invention, a maintenance method of treatment is provided, giving, as a preferred example, a dose of 5 mg/kg of carnitine.
The following table explains the preferred method for a 3-weeks treatment:
Such preferred therapeutic method for the treatment of chronic uraemic patients undergoing haemodialysis, included more particularly the following steps:
1) on the days between one haemodialytic session and the next, administration by the oral route to these patients of 3 to 6 g per day of carnitine or any of its pharmaceutically acceptable salts;
2) on the days of haemodialytic session, submission of these patients to dialysis using, as dialysing liquid, a solution containing a quantity of carnitine or of any of its pharmaceutically acceptable salts, sufficient to make a molar concentration of carnitine in the said solution at least equal to the molar concentration of the plasma carnitine of the patient under dialytic treatment.
By operating in such a manner, it is possible to avoid the loss of plasma carnitine which otherwise takes place during a haemodialytic session; the concentration of plasma carnitine remaining practically unchanged during the dialytic session.
In this manner, it is possible to avoid the tissue carnitine depletion, which is the long-term consequence of repeated losses of carnitine the patienl: undergoes during the successive dialytic sessions he is submitted to over a prolonged period of time.
Although for this purpose it is shown to be sufficient that the solution for the haemodialysis be equimolar in carnitine with respect to the blood of the patient under dialytic treatment, it is preferred to operate with a slightly more concentrated solution.
In practice, the haemodialysis solution contains 50 to 100, preferably 60 - 80 moles/litre of carnitine or of any of its pharmaceutically acceptable salts.
On the days of haemodialytic session, carnitine may also be administered partly by the oral route and partly by slow infusion. In this case, the overall quantity of carnitine administered shall not exceed approximately 10 g.
The therapeutic method disclosed in US 4,272,549 is effective in treating "post-dialysis syndrome", but presents a cumbersome schedule of treatment. This fact makes some problems to occur. The compliance of the patients, whose quality of life is already heavily affected, about the necessity of taking care by themselves of the oral self administration of a prescribed dosage of carnitine between the 2o dialytic sessions. There is also the problem of carnitine bioavailability through the oral route, which is subject to saturation mechanism and to some restrictions as to the absorption sites (Harper at al. Eur. J. Clin. Pharmacol. 1988; 35(5):555-62 and Matsuda Et Al. Biol Pharm. Bull 1998, Jul; 21 (7):752-5).
Also, the oral administration of carnitine to a chronic uraemic patient may give rise to the accumulation of toxic metabolites.
A recent work by Sloan et al. (Am. J. Kidney Dis. 1998, Aug;
32(2):265-72) demonstrated that oral supplementation of carnitine is 5 effective in improving the quality of life of patients in the early stage of treatment, but the perceived effect was not sustained through long term treatment (six months).
Summary of the invention It has now been found in a totally unexpected manner an io improved therapeutic method for the treatment of chronic uraemic patients undergoing periodical dialysis.
The method for the treatment of chronic uraemic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
As dialysis session both haemodialysis and peritoneal dialysis zo are intended.
The method according to the present invention provides the surprising improvement with respect to the method disclosed in US
4,272,549 to eliminate the need of the oral treatment, without affecting the maintenance of the correction of carnitine deficiency obtained by the administration of carnitine through intravenous route.
In one aspect, the invention provides use of from to 20 mg/kg body weight of L-carnitine or a 5 pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the use is repeated twice a week every 44 hours and then after 68 hours, and wherein the use 10 is repeated after 3 to 4 weeks with 5 mg/kg of body weight of L-carnitine as a maintenance dosage.
In a further aspect, the invention provides use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the amount of L-carnitine or a pharmaceutically acceptable salt thereof is effective to restore the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter using a maintenance dosage of L-carnitine or a pharmaceutically acceptable salt thereof in the venous return line sufficient to maintain blood L-carnitine at the pre-dialytic level.
In a still further aspect, the invention provides use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein from 10 to 20 mg/kg of body weight of L-carnitine or a pharmaceutically acceptable salt thereof, calculated as L-6a carnitine, is used to restore the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter using a maintenance dosage of L-carnitine or a pharmaceutically acceptable salt thereof sufficient to maintain blood L-carnitine at the pre-dialytic level.
According to one aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount of 400 to 3000 mg and is for administration after each dialysis session over a three or four week period three times a week at 44 hour intervals followed by a delay of 68 hours before the next week's first session, and when the three or four week period is over, the L-carnitine or the pharmaceutically acceptable salt is for administration in an amount of 200 to 750 mg as a maintenance dosage following each dialysis session.
According to another aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing pericdic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective for restoration of the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective as a maintenance 6b dosage of in the venous return line sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
According to still another aspect of the present invention, there is provided use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein from 400 to 3000 mg of the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration after the dialysis session in restoration of blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration as a maintenance dosage in an amount sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
The invention shall be disclosed in detail, with reference to Figures and Examples.
Brief description of the figures Figure 1 illustrates the treatment schedule, where the letters A-F denote the heart effluent sampling times for the measurement of metabolites.
Figure 2 shows the effect of carnitine (A) and carnitine fumarate (B) on creatine phosphate and ATP.
Figure 3 compares lactate (A) with succinate (B) released by the heart, as measured in the effluent.
Figure 4 illustrates the release of malate.
6c Figure 5 illustrates the release of LDH.
Figure 6 illustrates the production of lactate.
Detailed disclosure of the invention The preferred starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session.
Initiation of the therapy may be prompted by through (pre-dialysis) plasma carnitine concentrations that are below normal (40-50 mol/L). Dose adjustments should be guided by through (pre-dialysis) carnitine concentrations, and downward dose adjustments (for example to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.
Carnitine can be administered as inner salt or in any pharmaceutically acceptable salts thereof.
In the above mentioned patents US 4272549 and US 4272549, the invention is given in detailed manner as to put it into practice.
As far as carnitine is concerned, the active ingredient is mentioned as "carnitine or any of its pharmaceutically acceptable salts" (see for instance US 4272549, column 4, line 16), thus clearly teaching to io the skilled person that any of the pharmaceutically acceptable salts will do in the invention therein disclosed.
In the present invention we confirm that for the practice of the improved method for the treatment of chronic uraemic patients undergoing periodical dialysis, any of the pharmaceutically acceptable salts of carnitine will do. But, in a particular embodiment of the invention, the skilled person might have to face a problem with some patients. During the dialytic session, some patients are affected by hypervolemic heart, and this can give a severe outcome as heart failure. Moreover, a number of patients undergoing 2o hemodialysis are affected by diabetes.
In a particular embodiment of the present invention, it has been found that fumarate of L-carnitine exerts a surprising beneficial effect on heart. Moreover, due to its physiologic role, fumarate may have beneficial effects in diabetic patients.
WO 01/52836 PCT/ITOl/00012 Accordingly, a particular embodiment of the present invention relates to the method above disclosed, wherein fumarate is the pharmaceutically acceptable salt of L-carnitine.
Suitable formulations of carnitine, or a pharmaceutically acceptable salt thereof, are in the form of injectable compositions, for example comprising an equivalent amount of carnitine of 200 mg per 1 mL. A 2.5 or a 5 mL single dose ampoule may be convenient.
When a pharmaceutically acceptable salt of L-carnitine is used, such as fumarate, the amount of active ingredient shall be calculated as to to give an equivalent amount of L-carnitine as above specified.
Description of the preferred embodiment Patients showing a pre-dialysis carnitine level equal or lower than 40-50 M were treated with the method according to the present invention with a 10-20 mg/kg dose of carnitine at the end of the 4-hours dialytic session. According to a standard dialytic schedule, the treatment was repeated twice a week every 44 hours, then after 68 hours. This treatment was continued for 3-4 weeks, monitoring pre-dialytic levels of carnitine. As a further embodiment of the present invention, a maintenance method of treatment is provided, giving, as a preferred example, a dose of 5 mg/kg of carnitine.
The following table explains the preferred method for a 3-weeks treatment:
day of the week Dialysis Carnitine administration Monday X X
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Monday X X
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Monday X X
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Wherein X shows a 4-hours dialytic session and the carnitine intravenous administration according to the present invention at the end of the session. 44 hours occur between two subsequent carnitine administrations from Monday to Friday and 68 hours 5 occur between two subsequent carnitine administrations from Friday to Monday.
As far as the particular embodiment of L-carnitine fumarate, the following examples further illustrate the invention.
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Monday X X
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Monday X X
Tuesday Wednesday X X
Thursday Friday X X
Saturday Sunday Wherein X shows a 4-hours dialytic session and the carnitine intravenous administration according to the present invention at the end of the session. 44 hours occur between two subsequent carnitine administrations from Monday to Friday and 68 hours 5 occur between two subsequent carnitine administrations from Friday to Monday.
As far as the particular embodiment of L-carnitine fumarate, the following examples further illustrate the invention.
10 Effect of the administration of L-carnitine fumarate on the perfused heart In this example, the low-pressure or low-flow ischemia model was used, which is a model recognised as valid for cardiac ischemia (Bolukoglu, H. et al. Am. J. Physiol. 1996: 270; H817-26).
The treatment schedule is illustrated in Figure 1., in which the letters A-F denote the heart effluent sampling times for the measurement of metabolites. The hearts are removed from the animals and mounted on a Langerdorff appliance. The perfusion medium replacing the blood was a Krebs-Heinsleit standard 2o bicarbonate buffer containing glucose 12 mM as energy source for cardiac metabolism.
After 30 minute perfusion at a pressure of 100 cm of water, ischemia was induced by reducing the perfusion pressure of the heart to 25 cm of water, thus reducing coronary flow from approximately 2 ml/min to approximately 0.3 ml/min. Reduction of the perfusion pressure gives rise to ischemia, since the heart will pump the fluid in the low-perfusion area rather than via the coronary bloodstream, supplying the flow to the heart.
This control model was compared with hearts perfused with L-carnitine 10 mM or L-carnitine fumarate 10 mM.
Cardiac function was tested in three different ways.
In the first, the NRM 31P signal was monitored in real time.
This signal provides the best indication of the energy status of i o the heart.
In the second, the haemodynamics of the heart was measured by means of a pressure transducer mounted to measure the perfusion pressure. The haemodynamic measurements include heart rate, relative dP/dt (measurement of the contraction force of the is heart) and the cardiac contraction amplitude. Coronary flow was also measured as an indicator of the heart's ability to provide oxygen and energy for its own metabolism.
In the third type of test, the metabolites and the enzyme LDH
released by the heart were analysed in the effluent. The release of 2o LDH indicates damage to cardiac tissue. The release of metabolites by the heart was tested by means of mass spectrometry coupled with gas chromatography.
The results of the experiments show that the hearts treated with carnitine fumarate have reduced release of LDH; the reserves of high-energy phosphai--e after 45 minutes of ischemia are greater in treated hearts, as indicated by the increase in creatine phosphate observed at NMR and the profile of the metabolites released indicates that the treated heart generates less lactate, but more malate. A high lactate level indicates intense anaerobic metabolism and acidosis. The increase in malate indicates that fumarate is metabolised by the heart to yield a system of intermediates of the citric acid cycle favourable to the heart. Haemodynamic function, as indicated by the postischemic cardiac contraction amplitude and by 1o coronary flow, is greater in hearts treated with carnitine fumarate.
The procedures of example 1 were substantially repeated, with the addition of a treatment with carnitine alone as a further control.
The results are given in Figures 2-6, where:
Figure 2 illustrates the effect of carnitine (A) and carnitine fumarate (B) on creatine phosphate and ATP. The data were evaluated after 40 minutes of ischemia. CP indicates creatine phosphate and a,(3 and y denote the phosphate peaks of ATP; as can be seen in part (A) of the figure, the ATP peaks are lacking in the 2o absence of fumarate.
Figure 3 shows the comparison between lactate (A) and succinate (B) released by the heart, as measured in the effluent. The lactate reduction indicates the favourable effect of carnitine fumarate. The low amount of succinate as compared to lactate indicates that the generation of ATP as a result of the reduction of fumarate to succinate is not the main source of anaerobic ATP.
Figure 4 illustrates the release of malate. The greater malate levels in the treated heart indicate that fumarate enters the cardiac mitochondrion and is metabolised in the TCA cycle.
Figure 5 illustrates the release of LDH. The greater LDH levels in controls indicate that carnitine fumarate affords protection against ischemic damage.
Figure 6 illustrates lactate production.
The treatment schedule is illustrated in Figure 1., in which the letters A-F denote the heart effluent sampling times for the measurement of metabolites. The hearts are removed from the animals and mounted on a Langerdorff appliance. The perfusion medium replacing the blood was a Krebs-Heinsleit standard 2o bicarbonate buffer containing glucose 12 mM as energy source for cardiac metabolism.
After 30 minute perfusion at a pressure of 100 cm of water, ischemia was induced by reducing the perfusion pressure of the heart to 25 cm of water, thus reducing coronary flow from approximately 2 ml/min to approximately 0.3 ml/min. Reduction of the perfusion pressure gives rise to ischemia, since the heart will pump the fluid in the low-perfusion area rather than via the coronary bloodstream, supplying the flow to the heart.
This control model was compared with hearts perfused with L-carnitine 10 mM or L-carnitine fumarate 10 mM.
Cardiac function was tested in three different ways.
In the first, the NRM 31P signal was monitored in real time.
This signal provides the best indication of the energy status of i o the heart.
In the second, the haemodynamics of the heart was measured by means of a pressure transducer mounted to measure the perfusion pressure. The haemodynamic measurements include heart rate, relative dP/dt (measurement of the contraction force of the is heart) and the cardiac contraction amplitude. Coronary flow was also measured as an indicator of the heart's ability to provide oxygen and energy for its own metabolism.
In the third type of test, the metabolites and the enzyme LDH
released by the heart were analysed in the effluent. The release of 2o LDH indicates damage to cardiac tissue. The release of metabolites by the heart was tested by means of mass spectrometry coupled with gas chromatography.
The results of the experiments show that the hearts treated with carnitine fumarate have reduced release of LDH; the reserves of high-energy phosphai--e after 45 minutes of ischemia are greater in treated hearts, as indicated by the increase in creatine phosphate observed at NMR and the profile of the metabolites released indicates that the treated heart generates less lactate, but more malate. A high lactate level indicates intense anaerobic metabolism and acidosis. The increase in malate indicates that fumarate is metabolised by the heart to yield a system of intermediates of the citric acid cycle favourable to the heart. Haemodynamic function, as indicated by the postischemic cardiac contraction amplitude and by 1o coronary flow, is greater in hearts treated with carnitine fumarate.
The procedures of example 1 were substantially repeated, with the addition of a treatment with carnitine alone as a further control.
The results are given in Figures 2-6, where:
Figure 2 illustrates the effect of carnitine (A) and carnitine fumarate (B) on creatine phosphate and ATP. The data were evaluated after 40 minutes of ischemia. CP indicates creatine phosphate and a,(3 and y denote the phosphate peaks of ATP; as can be seen in part (A) of the figure, the ATP peaks are lacking in the 2o absence of fumarate.
Figure 3 shows the comparison between lactate (A) and succinate (B) released by the heart, as measured in the effluent. The lactate reduction indicates the favourable effect of carnitine fumarate. The low amount of succinate as compared to lactate indicates that the generation of ATP as a result of the reduction of fumarate to succinate is not the main source of anaerobic ATP.
Figure 4 illustrates the release of malate. The greater malate levels in the treated heart indicate that fumarate enters the cardiac mitochondrion and is metabolised in the TCA cycle.
Figure 5 illustrates the release of LDH. The greater LDH levels in controls indicate that carnitine fumarate affords protection against ischemic damage.
Figure 6 illustrates lactate production.
Claims (17)
1. Use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount of 400 to 3000 mg and is for administration after each dialysis session over a three or four week period three times a week at 44 hour intervals followed by a delay of 68 hours before the next week's first session, and when the three or four week period is over, the L-carnitine or the pharmaceutically acceptable salt is for administration in an amount of 200 to 750 mg as a maintenance dosage following each dialysis session.
2. The use of claim 1, wherein the pre-dialytic levels of blood L-carnitine are equal to or lower than 40-50 µM.
3. The use of claim 1 or 2, wherein L-carnitine fumarate is the pharmaceutically acceptable salt.
4. The use of any one of claims 1 to 3, wherein the patient is affected by a hypervolemic heart.
5. The use of any one of claims 1 to 3, wherein the patient is affected by diabetes.
6. Use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective for restoration of the blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter wherein the L-carnitine or the pharmaceutically acceptable salt thereof is for administration in an amount effective as a maintenance dosage of in the venous return line sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
7. The use of claim 6, wherein the administration for restoration to the at least pre-dialytic blood L-carnitine level is following each dialysis session, three times a week at 44 hour intervals, followed by a delay of 68 hours before the next week's first session.
8. The use of claim 7, wherein the administration for restoration to the at least pre-dialytic blood L-carnitine level is in an amount of 400 to 3000 mg of the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine.
9. The use of any one of claims 6 to 8, wherein the pre-dialytic level of blood L-carnitine is equal to or lower than 40-50 µM.
10. The use of any one of claims 6 to 9, wherein L-carnitine fumarate is the pharmaceutically acceptable salt.
11. The use of any one of claims 6 to 10, wherein the patient is affected by a hypervolemic heart.
12. The use of any one of claims 6 to 10, wherein the patient is affected by diabetes.
13. Use of L-carnitine or a pharmaceutically acceptable salt thereof in a venous return line after a dialysis session for preventing or treating L-carnitine deficiency in a chronic uraemic patient undergoing periodic dialysis, wherein from 400 to 3000 mg of the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration after the dialysis session in restoration of blood level of L-carnitine in the patient to at least a pre-dialytic level and thereafter the L-carnitine or the pharmaceutically acceptable salt thereof, calculated as L-carnitine, is for administration as a maintenance dosage in an amount sufficient for maintenance of blood L-carnitine at the pre-dialytic level.
14. The use of claim 13, wherein the administration for restoration of the at least pre-dialytic blood L-carnitine level is following each dialysis session, three times a week at 44 hour intervals, followed by a delay of 68 hours before the next week's first session.
15. The use of claim 13 or 14, wherein the pre-dialytic blood level of L-carnitine is equal to or lower than 40-50 µM.
16. The use of any one of claims 13 to 15, wherein the maintenance dosage of the L-carnitine or the pharmaceutically acceptable salt thereof is 200 to 750 mg.
17. The use of any one of claims 13 to 16, wherein the patient is affected by a hypervolemic heart.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17662900P | 2000-01-19 | 2000-01-19 | |
| US60/176,629 | 2000-01-19 | ||
| US18632800P | 2000-03-02 | 2000-03-02 | |
| US60/186,328 | 2000-03-02 | ||
| PCT/IT2001/000012 WO2001052836A1 (en) | 2000-01-19 | 2001-01-15 | Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2381187A1 CA2381187A1 (en) | 2001-07-26 |
| CA2381187C true CA2381187C (en) | 2009-06-02 |
Family
ID=26872436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002381187A Expired - Fee Related CA2381187C (en) | 2000-01-19 | 2001-01-15 | Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1257266A1 (en) |
| AU (1) | AU2001230502A1 (en) |
| CA (1) | CA2381187C (en) |
| WO (1) | WO2001052836A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (en) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | THERAPEUTIC APPLICATION OF CARNITINE AND SOME ACYLATED DERIVATIVES OF CARNITINE IN HEMODIALYSIS |
| US6537976B1 (en) * | 1997-08-07 | 2003-03-25 | Ajay Gupta | Dialysis solutions containing water soluble vitamins and nutrients |
-
2001
- 2001-01-15 AU AU2001230502A patent/AU2001230502A1/en not_active Abandoned
- 2001-01-15 WO PCT/IT2001/000012 patent/WO2001052836A1/en active Application Filing
- 2001-01-15 EP EP01902636A patent/EP1257266A1/en not_active Withdrawn
- 2001-01-15 CA CA002381187A patent/CA2381187C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001230502A1 (en) | 2001-07-31 |
| EP1257266A1 (en) | 2002-11-20 |
| CA2381187A1 (en) | 2001-07-26 |
| WO2001052836A1 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0249667B1 (en) | Fluid therapy with l-lactate and/or pyruvate anions | |
| US6429230B1 (en) | Treating chronic uremic patients undergoing periodical dialysis | |
| Heistad et al. | Effects of adrenergic stimulation on ventilation in man | |
| US6075031A (en) | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders | |
| Reilly et al. | Ultra‐short‐acting beta‐blockade: a comparison with conventional beta‐blockade | |
| US6822002B1 (en) | Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use | |
| US6020007A (en) | Fluid therapy with l-lactate and/or pyruvate anions | |
| US6914076B2 (en) | Treating chronic uremic patients undergoing periodical dialysis | |
| US6335369B1 (en) | Treating chronic uremic patients undergoing periodical dialysis | |
| US4794124A (en) | Therapeutic composition for diabetic complications | |
| CA2381187C (en) | Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis | |
| Elmfeldt et al. | Antihypertensive effects of felodipine compared with placebo | |
| CA2305183C (en) | Postsurgical treatment with dichloroacetate | |
| ES2250749T3 (en) | USE OF A COMBINED COMPOSITION THAT INCLUDES PROPIONIL L-CARNITINE AND OTHER PHARMACOS FOR THE TREATMENT OF ERECTILE DYSFUNCTION. | |
| IL110006A (en) | Pharmaceutical compositions with sensoric block and minimal motor blockade comprising ropivacaine salts | |
| MXPA02000912A (en) | Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy. | |
| AU742013B2 (en) | Composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of CRPS | |
| USRE38604E1 (en) | Fluid therapy with L-lactate and/or pyruvate anions | |
| Gennari | Comparative physiology of acetate and bicarbonate alkalinization | |
| Tramonti et al. | Antihypertensive activity and renal effects of benazepril in humans. | |
| RU2479873C1 (en) | Method of endothelial dysfunction correction by combination of helium and oxygen in l-name induced nitrogen oxide deficiency | |
| NHCHCH | Ultra-short-acting beta-blockade: A comparison with conventional | |
| AU1496600A (en) | Fluid therapy with L-lactate and/or pyruvate anions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150115 |